Q3 2025 · 13F-HR
Ally Bridge Group (NY) LLCholdings as filed
Filed 2025-11-14 · accession 0001193125-25-283054
$164.2M
Reported value
24
Positions
2025-09-30
Period end
The Brief · Ally Bridge Group (NY) LLC · Q3 2025
AI · grounded in 13F
Ally Bridge Group (NY) LLC closed its position in VRNA for a reduction of $15.2M. The fund established new positions in MDGL for $15.0M and ATAI BECKLEY NV for $12.1M. Additionally, the fund accumulated shares in REPL by 581.2% and SLNO by 209%.
Holdings as filed
| CUSIP | Ticker | Issuer | Value | % port. | Shares | Class | Voting |
|---|---|---|---|---|---|---|---|
| 834203309 | SLNO | SOLENO THERAPEUTICS INC | $20.4M | 12.5% | 302,483 | Common | SOLE |
| 834203309 | SLNO | SOLENO THERAPEUTICS INC | $16.9M | 10.3% | 250,000 | CALL | SOLE |
| 76029N106 | REPL | REPLIMUNE GROUP INC | $15.1M | 9.19% | 3,600,000 | CALL | SOLE |
| 558868105 | MDGL | MADRIGAL PHARMACEUTICALS INC | $15.0M | 9.12% | 32,662 | Common | SOLE |
| N0731H103 | ATAI | ATAI BECKLEY NV | $12.1M | 7.37% | 2,287,005 | Common | SOLE |
| 04351P101 | ASNDUSD | ASCENDIS PHARMA A/S - ADR | $10.2M | 6.18% | 51,080 | Common | SOLE |
| 52635N103 | LENZ | LENZ THERAPEUTICS INC | $8.2M | 4.97% | 175,363 | Common | SOLE |
| 20451W101 | CMPS | COMPASS PATHWAYS PLC | $6.6M | 4.00% | 1,145,700 | CALL | SOLE |
| 877619106 | TSHA | TAYSHA GENE THERAPIES INC | $6.2M | 3.78% | 1,898,112 | Common | SOLE |
| 03237H101 | AMLX | AMYLYX PHARMACEUTICALS INC | $5.9M | 3.62% | 437,391 | Common | SOLE |
| 20451W101 | CMPS | COMPASS PATHWAYS PLC | $5.9M | 3.58% | 1,026,382 | Common | SOLE |
| 29842P105 | EPRX | EUPRAXIA PHARMACEUTICALS INC | $5.4M | 3.29% | 915,000 | Common | SOLE |
| 74006W207 | PRAX | PRAXIS PRECISION MEDICINES I | $5.3M | 3.23% | 100,000 | CALL | SOLE |
| 61023L207 | MNPR | MONOPAR THERAPEUTICS INC | $5.3M | 3.21% | 64,455 | Common | SOLE |
| 03969K108 | ARQT | ARCUTIS BIOTHERAPEUTICS INC | $4.4M | 2.68% | 233,220 | Common | SOLE |
| 60255C885 | BRD1EUR | MIND MEDICINE MINDMED INC | $4.3M | 2.60% | 361,444 | Common | SOLE |
| 87650L103 | TARS | TARSUS PHARMACEUTICALS INC | $4.2M | 2.56% | 70,778 | Common | SOLE |
| 83422E204 | SLDB | SOLID BIOSCIENCES INC | $3.4M | 2.06% | 549,182 | Common | SOLE |
| 74346M406 | PMNEUR | PROMIS NEUROSCIENCES INC | $2.6M | 1.61% | 6,233,497 | Common | SOLE |
| 05338F306 | AVTX | AVALO THERAPEUTICS INC | $2.3M | 1.38% | 178,100 | Common | SOLE |
| 878972108 | TECX | TECTONIC THERAPEUTIC INC | $2.2M | 1.32% | 138,595 | Common | SOLE |
| 00032Q104 | WHWK | WHITEHAWK THERAPEUTICS INC | $1.6M | 0.95% | 817,939 | Common | SOLE |
| 61559X104 | MLTX | MOONLAKE IMMUNOTHERAPEUTICS | $494,730 | 0.30% | 69,000 | CALL | SOLE |
| 002120202 | ATYR | ATYR PHARMA INC | $432,840 | 0.26% | 600,000 | CALL | SOLE |
Source: SEC EDGAR · raw 13F holdings as filed. The Class column shows the option type when reported (Put/Call) or Common when the issuer's equity is held directly. 13F discloses long positions only.